AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit
pharmafile | May 20, 2019 | News story | Research and Development, Sales and Marketing | AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure
AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed glioblastoma (GBM) in patients whose tumours have epidermal growth factor receptor (EGFR) amplification, after it was identified in an interim analysis that the therapy presented no survival benefit to patients.
The disappointing news comes after an Independent Data Monitoring Committee (IDMC) discovered that the drug, when combined with the standard regimen of radiation and temozolomide, lacked survival benefit compared to placebo, and thus recommended that the trial be stopped.
“Glioblastoma patients and their caregivers face a devastating disease for which there are few therapeutic options. While we are disappointed that Depatux-M did not demonstrate a survival benefit in the INTELLANCE-1 study, we remain committed to discovering and developing therapies to address some of the most debilitating cancers,” explained Dr Michael Severino, Vice Chairman and President at AbbVie.
The company also announced that enrolment has been placed on hold for all ongoing studies involving Depatux-M.
Matt Fellows
Related Content
Medincell and AbbVie enter agreement for development of next-generation injectables
Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and …
Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine
Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …